TP53 and breast carcinoma: Two breast cancer cell lines MCF7 (p53 wild-type, ER positive) and MDA-MB-231 (p53 mutant, triple negative) were selected based on their genetic backgrounds for investigating the in vitro activity of InuA and its molecular mechanisms.